BG106057A - Метод за подобряване на ефикасността на антитуморни средства - Google Patents

Метод за подобряване на ефикасността на антитуморни средства

Info

Publication number
BG106057A
BG106057A BG106057A BG10605701A BG106057A BG 106057 A BG106057 A BG 106057A BG 106057 A BG106057 A BG 106057A BG 10605701 A BG10605701 A BG 10605701A BG 106057 A BG106057 A BG 106057A
Authority
BG
Bulgaria
Prior art keywords
enhancing
efficacy
tumour agents
tumour
agents
Prior art date
Application number
BG106057A
Other languages
English (en)
Other versions
BG64940B1 (bg
Inventor
Steven Piver
David Silver
Original Assignee
Health Research, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Research, Inc. filed Critical Health Research, Inc.
Publication of BG106057A publication Critical patent/BG106057A/bg
Publication of BG64940B1 publication Critical patent/BG64940B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • External Artificial Organs (AREA)

Abstract

Методът се прилага за подобряване ефекта на антитуморни средства, по-специално върху твърди тумори.Методът включва прилагане на противотуморно средство и средство за повишаване на хематокрита, коетоможе да бъде приложено преди или успоредно с антитуморното средство.
BG106057A 1999-04-27 2001-10-26 Метод за подобряване на ефикасността на антитуморни средства BG64940B1 (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/300,124 US6171620B1 (en) 1999-04-27 1999-04-27 Method of enhancing the efficacy of anti-tumor agents

Publications (2)

Publication Number Publication Date
BG106057A true BG106057A (bg) 2002-04-30
BG64940B1 BG64940B1 (bg) 2006-10-31

Family

ID=23157813

Family Applications (1)

Application Number Title Priority Date Filing Date
BG106057A BG64940B1 (bg) 1999-04-27 2001-10-26 Метод за подобряване на ефикасността на антитуморни средства

Country Status (18)

Country Link
US (3) US6171620B1 (bg)
EP (1) EP1212068A4 (bg)
JP (1) JP2002542296A (bg)
KR (1) KR100693796B1 (bg)
CN (1) CN1188137C (bg)
AU (1) AU781301B2 (bg)
BG (1) BG64940B1 (bg)
BR (1) BR0010082A (bg)
CA (1) CA2368618C (bg)
HU (1) HUP0200840A3 (bg)
IL (1) IL146012A0 (bg)
MX (1) MXPA01010899A (bg)
NO (1) NO20015227L (bg)
NZ (1) NZ514521A (bg)
PL (1) PL350918A1 (bg)
RU (1) RU2271829C2 (bg)
WO (1) WO2000064455A1 (bg)
ZA (1) ZA200108012B (bg)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050142217A1 (en) * 2000-04-26 2005-06-30 Adams Michael A. Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
US7678391B2 (en) * 2000-04-26 2010-03-16 Queen's University At Kingston Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
JP2003531179A (ja) 2000-04-26 2003-10-21 クイーンズ ユニバーシティ アット キングストン 悪性細胞表現型に対し一酸化窒素模倣体を使用する処方および方法
DE60332358D1 (de) * 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
CN104383542B (zh) 2003-04-08 2017-09-26 普罗热尼奇制药公司 包含甲基纳曲酮的药物配方
DE10361813A1 (de) * 2003-12-30 2005-09-08 Bionethos Holding Gmbh Verfahren zur Regeneration von Gewebe
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
MX2007010833A (es) * 2005-03-07 2009-02-17 Univ Chicago Uso de antagonistas opioides para atenuar proliferacion y migracion de células endoteliales.
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
JP2010510794A (ja) 2006-11-28 2010-04-08 ハナル ファーマシューティカル カンパニー リミテッド 修飾型エリスロポエチンポリペプチド及びこの治療用用途
SI2139890T1 (sl) 2007-03-29 2014-12-31 Wyeth Llc Antagonisti perifernih opioidnih receptorjev in njih uporaba
PA8774201A1 (es) 2007-03-29 2009-06-23 Progenics Pharm Inc Antagonista del receptor
MX351611B (es) 2007-03-29 2017-10-20 Wyeth Llc Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas.
EP2730578A1 (en) 2008-02-06 2014-05-14 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnal trexone
EP2278966B1 (en) 2008-03-21 2019-10-09 The University of Chicago Treatment with opioid antagonists and mtor inhibitors
CA2723621A1 (en) * 2008-05-15 2009-11-19 Edison Pharmaceuticals, Inc Treatment of hearing and balance impairments using compounds having erythropoietin activity
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
PL230756B1 (pl) * 2015-09-11 2018-12-31 Univ Medyczny W Bialymstoku Erytropoetyna oraz inhibitor kinazy Brutona w postaci 2- cyjan o-N-( 2,5-dibromofenylo)- 3-hydroksy-2- butenamidu do zastosowania jako lek oraz ich zastosowanie do wytwarzania leku do terapii nowotworu
JPWO2019083023A1 (ja) * 2017-10-26 2020-11-12 国立大学法人 筑波大学 癌の治療に使用するための組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745099A (en) * 1985-02-06 1988-05-17 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for the treatment of the anemia of malignant tumors
JP2632014B2 (ja) * 1988-03-03 1997-07-16 中外製薬株式会社 骨髄機能障害性貧血治療剤
JPH1067678A (ja) * 1996-06-20 1998-03-10 Chugai Pharmaceut Co Ltd 肝疾患治療用医薬組成物
US20020052309A1 (en) * 1996-09-11 2002-05-02 Athanasius A. Anagnostou Method of treating endothelial injury

Also Published As

Publication number Publication date
US6620779B2 (en) 2003-09-16
NO20015227D0 (no) 2001-10-25
US6171620B1 (en) 2001-01-09
CA2368618C (en) 2011-03-01
EP1212068A1 (en) 2002-06-12
AU781301B2 (en) 2005-05-12
BR0010082A (pt) 2002-01-15
CA2368618A1 (en) 2000-11-02
NZ514521A (en) 2003-07-25
MXPA01010899A (es) 2003-06-24
CN1352561A (zh) 2002-06-05
PL350918A1 (en) 2003-02-10
RU2271829C2 (ru) 2006-03-20
JP2002542296A (ja) 2002-12-10
KR20020000557A (ko) 2002-01-05
ZA200108012B (en) 2003-03-26
BG64940B1 (bg) 2006-10-31
IL146012A0 (en) 2002-07-25
HUP0200840A2 (hu) 2002-07-29
WO2000064455A1 (en) 2000-11-02
KR100693796B1 (ko) 2007-03-12
AU4486300A (en) 2000-11-10
US20020198153A1 (en) 2002-12-26
CN1188137C (zh) 2005-02-09
HUP0200840A3 (en) 2003-04-28
NO20015227L (no) 2001-12-27
EP1212068A4 (en) 2007-03-14
US20010000730A1 (en) 2001-05-03
US6426094B2 (en) 2002-07-30

Similar Documents

Publication Publication Date Title
BG106057A (bg) Метод за подобряване на ефикасността на антитуморни средства
HRP920632A2 (en) Oral composition for the treatment of inflammatory l deseases
IL140930A0 (en) Compounds and compositions for delivering active agents
CY2473B1 (en) New phenanthridines.
IL140710A0 (en) Pulmonary delivery of active agents
EP1015008A4 (en) COMPOUNDS AND COMPOSITIONS FOR THE ADMINISTRATION OF ACTIVE SUBSTANCES
PL350658A1 (en) Medical preparations for the treatment of alpha−galactosidase a deficiency
MXPA01008611A (es) Compuestos y composiciones para suministrar agentes activos.
ATE168560T1 (de) Topische mittel zur transdermalen verabreichung von prodrugderivaten des morphins
DE69905368D1 (en) Oxydiertes thymosin beta 4
ZA941525B (en) Use of riluzole in the treatment of nero-AIDS
PT1007055E (pt) Utilizacao de amifostina
IL140588A0 (en) Therapeutic composition based on flavonoids intended to be used in the treatment of tumours by cytotoxic agents
EP1023901A4 (en) MEDICINES FOR HEPATITIS C AND THE USE THEREOF
WO1999021574A3 (en) Enhancement of morphogen activity
PT1150703E (pt) Terapia de esclerose multipla com chaperonina 10 e beta-interferao
SE9800905L (sv) Ny terapi vid glomerulonefrit
EP1173186A4 (en) USE OF TAGATOSIS TO INCREASE KEY BLOOD FACTORS
EP1347754A4 (en) COMPOSITIONS FOR PREVENTION OF ADHESION
MD980129A (en) Antiherpetic remedy
TR200000728T2 (tr) Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.
EP1374873A4 (en) USE OF N-ACETYL-D-GLUCOSAMINE IN THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS FOR THE SUPPRESSION OF SIDE EFFECTS CAUSED BY RADIATION THERAPY AND CHEMOTHERAPY
EP1143981A4 (en) TREATMENT AND PREVENTION OF HIV AND OTHER VIRUS INFECTIONS
NZ331374A (en) Phenanthridine compounds and pharmaceutical compositions thereof
PL365075A1 (en) Combinations of dalfopristine/quinupristine with cefpirome